Healthcare Services

CRISPR gene editing market expected to reach $8.28B by 2030

April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The CRISPR Gene Editing Market Expected To Reach Based On Its 2026 Value?

The crispr gene editing market size has experienced rapid expansion in recent years. It is anticipated to expand from $2.88 billion in 2025 to $3.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 27.1%. The increase observed in the past period can be linked to the demand for accurate gene modification tools, the inadequacies of earlier gene editing technologies, the expansion of genomics research, its adoption within academic institutions, and financial support for genetic research.

The crispr gene editing market is projected to experience substantial growth in the coming years. It is anticipated to reach $8.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.7%. This expansion during the forecast period is primarily due to the approval of gene editing therapies, the increasing adoption of precision medicine, advancements in agricultural biotechnology, the development of robust regulatory frameworks, and ongoing technological enhancements of crispr systems. Furthermore, major trends influencing this period include the surge in clinical gene therapy research, the broadening application of agricultural gene editing, the rise of functional genomics studies, innovations in delivery technologies, and a growing emphasis on ethical and regulatory compliance.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Which Drivers Are Supporting The CRISPR Gene Editing Market Growth?

The rising occurrence of genetic disorders is anticipated to drive expansion in the CRISPR gene editing market going forward. A genetic disorder represents a health issue originating from abnormalities in the genome, which can include mutations within a single gene (monogenic), multiple genes (polygenic), or chromosomal irregularities. The frequency of genetic disorders is increasing due to genetic mutations, aging populations, and consanguineous marriage. CRISPR gene editing provides significant assistance in managing genetic disorders by enabling precise and targeted modifications to DNA. Furthermore, scientists utilize CRISPR to identify and correct specific mutations causing genetic disorders, aiming to restore normal function and alleviate disease symptoms, as observed in conditions like cystic fibrosis and sickle cell anaemia. For instance, in October 2025, according to the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2024, there were 164 new diagnoses of cystic fibrosis (CF), with 123 of these identified through newborn screening. By the end of 2024, there were 11,381 individuals registered with CF. Consequently, the escalating prevalence of genetic disorders is propelling the growth of the CRISPR gene editing market.

Which Segment Categories Are Included In The CRISPR Gene Editing Market Segment Analysis?

The crispr gene editing market covered in this report is segmented –

1) By Type: CRISPR-Associated Nuclease (Cas Nuclease), Guide Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA) Ligase, Restriction Endonuclease, Other Types

2) By Services: Design Tools, Plasmid And Vector, CRISPR-Associated Protein 9 (Cas9) And Guide Ribonucleic Acid (g-RNA), Delivery System Products, Other Services

3) By Technology: CRISPR Or Cas9, Zinc Finger Nucleases, Other Technologies

4) By Application: Agricultural, Biomedical, Industrial, Genome Engineering, Disease Models, Functional Genomics, Other Applications

5) By End User: Academic Institutes And Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical And Biopharmaceutical Companies

Subsegments:

1) By CRISPR-Associated Nuclease (Cas Nuclease): Cas9, Cas12, Cas13

2) By Guide Ribonucleic Acid (RNA): Single-Guide RNA (sgRNA), Dual-Guide RNA, Synthetic Guide RNA

3) By Deoxyribonucleic Acid (DNA) Ligase: T4 DNA Ligase, E. Coli DNA Ligase

4) By Restriction Endonuclease: Type II Restriction Enzymes, Type I And III Restriction Enzymes

5) By Other Types: CRISPR Delivery Systems, CRISPR Plasmids, CRISPR-Based Diagnostic Tools

Which Trends Are Expected To Impact The CRISPR Gene Editing Market?

Leading companies operating in the CRISPR gene editing market are concentrating on developing innovative products, such as gene therapy, to reach broader customer bases, increase sales, and boost revenue. Gene therapy is a medical approach that uses genes to treat, prevent, or cure various diseases and disorders. For example, in December 2023, the US Food and Drug Administration (FDA), a US-based federal agency, approved Casgevy, a cell-based gene therapy, for addressing sickle cell disease. Casgevy therapy leverages CRISPR/Cas9, a form of genome editing technology, by modifying hematopoietic stem cells.

Who Are The Active Companies Shaping The CRISPR Gene Editing Market?

Major companies operating in the crispr gene editing market are Crispr Therapeutics, Thermo Fisher Scientific, Intellia Therapeutics, Horizon Discovery, Synthego Corporation, Integrated DNA Technology (Danaher), Editas Medicine, GenScript, Agilent Technologies, New England Biolabs, CSIR-Institute of Genomics & Integrative Biology (IGIB), Strand Life Sciences Pvt. Ltd., Bio Palette Co. Ltd., Churchi Genome Engineering and Therapeutic Research Center, Beam Therapeutics Inc., Eurofins Genomics India, Setsurotech Co. Ltd., Merck Japan, Institut Pasteur, CureVac, Cellectis, BiovelocITA S.r.l., Evotec A.G., SNIPR Biome, Oxford Genetics, ERS Genomics, Alia Therapeutics, Solvo, BioTalentum, BIOCAD, BioVendor, Research & Diagnostic Products, Contipro, Lonza Biotec, Sotio, Selvita, BioVentures Institute Ltd, Sigma-Aldrich, Poseida Therapeutics, NanoCellect Biomedical, Sherlock Biosciences, Repare Therapeutics, Inscripta Inc., Santa Cruz Biotechnology, Caribou Biosciences Inc., Egenesis Inc., Homology Medicines, System Biosciences, Takara Bio USA Inc., Inari Agriculture Inc., Precision BioSciences, Cell Microsystems Inc., GeneCopoeia Inc., Merck KGaA, Origene Technologies Inc., Pluristem Therapeutics Inc.

Get The Full CRISPR Gene Editing Market Report:

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Which Geographic Region Dominates The CRISPR Gene Editing Market?

North America was the largest region in the CRISPR gene editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr gene editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized CRISPR Gene Editing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Browse Through More Reports Similar to the Global CRISPR Gene Editing Market 2026, By The Business Research Company

Crispr And Cas Gene Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Crispr Technology Market 2026

https://www.thebusinessresearchcompany.com/report/crispr-technology-market

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795